東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Repurposing the Human Immunodeficien...

Pennington, Matthew Robert.

Linked to FindBook

Google Book

Amazon

博客來

Repurposing the Human Immunodeficiency Virus (HIV) Integrase Inhibitor Raltegravir for the Treatment of Felid Alphaherpesvirus 1 (FHV-1) Ocular Infection.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Repurposing the Human Immunodeficiency Virus (HIV) Integrase Inhibitor Raltegravir for the Treatment of Felid Alphaherpesvirus 1 (FHV-1) Ocular Infection./
Author:	Pennington, Matthew Robert.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
Description:	274 p.
Notes:	Source: Dissertations Abstracts International, Volume: 80-03, Section: B.
Contained By:	Dissertations Abstracts International80-03B.
Subject:	Virology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10844170
ISBN:	9780438343283

Repurposing the Human Immunodeficiency Virus (HIV) Integrase Inhibitor Raltegravir for the Treatment of Felid Alphaherpesvirus 1 (FHV-1) Ocular Infection.
Pennington, Matthew Robert.

Repurposing the Human Immunodeficiency Virus (HIV) Integrase Inhibitor Raltegravir for the Treatment of Felid Alphaherpesvirus 1 (FHV-1) Ocular Infection. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 274 p.

Source: Dissertations Abstracts International, Volume: 80-03, Section: B.

Thesis (Ph.D.)--Cornell University, 2018.

This item is not available from ProQuest Dissertations & Theses.

Herpesviruses infect many species, inducing a wide range of diseases. Herpesvirus-induced ocular disease, which may lead to blindness, commonly occurs in humans, dogs, and cats, and is caused by human alphaherpesvirus 1 (HHV-1), canid alphaherpesvirus (CHV-1), and felid alphaherpesvirus 1 (FHV-1), respectively. Rapid and effective antiviral therapy is of the utmost importance to control infection in order to preserve the vision of infected people or animals. However, current treatment options are suboptimal, in large part due to the difficulty and cost of de novo drug development and the lack of effective models to bridge work in in vitro cell cultures and in vivo. Repurposing currently approved drugs for viral infections is one strategy to more rapidly identify new therapeutics. Furthermore, studying ocular herpesviruses in cats is of particular importance, as this condition is a frequent disease manifestation in these animals and FHV-1 infection of the cat is increasingly being recognized as a valuable natural-host model of herpesvirus-induced ocular infection First, the current models to study ocular herpesvirus infections were reviewed. Next, the efficacy of raltegravir was evaluated using a novel corneal explant model. Raltegravir is a human immunodeficiency virus (HIV) integrase inhibitor that was recently shown to poses antiviral activity against human herpesviruses. Then, electric cell-substrate impedance sensing (ECIS) was evaluated as a novel methodology to study the replication kinetics of herpesviruses. It was also used to characterize a fluorescently labeled FHV-1, created using CRISPR/Cas9 genome. Next, it was found that raltegravir inhibits both viral DNA synthesis initiation and late gene expression, a mechanism consistent with inhibition of viral ICP8. Finally, RNA sequencing was used to explore the indirect effects of raltegravir on the host. It was found that raltegravir treatment promoted the expression of anti-angiogenic factors and altered the metabolism of the host cells, both of which may be beneficial therapeutically. These results, combined with a recent in vivo study in experimentally infected cats, demonstrates that raltegravir is a viable treatment option for FHV-1 and warrants further investigations into its clinical potential against other herpesviruses.

ISBN: 9780438343283Subjects--Topical Terms:

642304
Virology.
Subjects--Index Terms:

Electric cell-substrate impedance sensing (ECIS)

Repurposing the Human Immunodeficiency Virus (HIV) Integrase Inhibitor Raltegravir for the Treatment of Felid Alphaherpesvirus 1 (FHV-1) Ocular Infection.
LDR:03789nmm a2200409 4500 001 2272255
005 20201105110006.5
008 220629s2018 ||||||||||||||||| ||eng d
020 $a 9780438343283
035 $a (MiAaPQ)AAI10844170
035 $a (MiAaPQ)cornellgrad:10972
035 $a AAI10844170
040 $a MiAaPQ $c MiAaPQ
100 1 $a Pennington, Matthew Robert. $3 3549687
245 1 0 $a Repurposing the Human Immunodeficiency Virus (HIV) Integrase Inhibitor Raltegravir for the Treatment of Felid Alphaherpesvirus 1 (FHV-1) Ocular Infection.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 274 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-03, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Walle, Gerlinde R. Van de.
502 $a Thesis (Ph.D.)--Cornell University, 2018.
506 $a This item is not available from ProQuest Dissertations & Theses.
506 $a This item must not be sold to any third party vendors.
520 $a Herpesviruses infect many species, inducing a wide range of diseases. Herpesvirus-induced ocular disease, which may lead to blindness, commonly occurs in humans, dogs, and cats, and is caused by human alphaherpesvirus 1 (HHV-1), canid alphaherpesvirus (CHV-1), and felid alphaherpesvirus 1 (FHV-1), respectively. Rapid and effective antiviral therapy is of the utmost importance to control infection in order to preserve the vision of infected people or animals. However, current treatment options are suboptimal, in large part due to the difficulty and cost of de novo drug development and the lack of effective models to bridge work in in vitro cell cultures and in vivo. Repurposing currently approved drugs for viral infections is one strategy to more rapidly identify new therapeutics. Furthermore, studying ocular herpesviruses in cats is of particular importance, as this condition is a frequent disease manifestation in these animals and FHV-1 infection of the cat is increasingly being recognized as a valuable natural-host model of herpesvirus-induced ocular infection First, the current models to study ocular herpesvirus infections were reviewed. Next, the efficacy of raltegravir was evaluated using a novel corneal explant model. Raltegravir is a human immunodeficiency virus (HIV) integrase inhibitor that was recently shown to poses antiviral activity against human herpesviruses. Then, electric cell-substrate impedance sensing (ECIS) was evaluated as a novel methodology to study the replication kinetics of herpesviruses. It was also used to characterize a fluorescently labeled FHV-1, created using CRISPR/Cas9 genome. Next, it was found that raltegravir inhibits both viral DNA synthesis initiation and late gene expression, a mechanism consistent with inhibition of viral ICP8. Finally, RNA sequencing was used to explore the indirect effects of raltegravir on the host. It was found that raltegravir treatment promoted the expression of anti-angiogenic factors and altered the metabolism of the host cells, both of which may be beneficial therapeutically. These results, combined with a recent in vivo study in experimentally infected cats, demonstrates that raltegravir is a viable treatment option for FHV-1 and warrants further investigations into its clinical potential against other herpesviruses.
590 $a School code: 0058.
650 4 $a Virology. $3 642304
650 4 $a Veterinary services. $3 3433982
653 $a Electric cell-substrate impedance sensing (ECIS)
653 $a Explant
653 $a Felid alphaherpesvirus (FHV-1)
653 $a ICP8
653 $a Ocular herpesvirus
653 $a Raltegravir
690 $a 0720
690 $a 0778
710 2 $a Cornell University. $b Immunology & Infectious Disease. $3 3549688
773 0 $t Dissertations Abstracts International $g 80-03B.
790 $a 0058
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10844170